Eligo Bioscience Stock

Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals.

Sign up today and learn more about Eligo Bioscience Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Eligo Bioscience Stock

Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.

Funding History

July 2015$2.6M
September 2017$2.0M
September 2017$18.0M
April 2018$1.8M
January 2019$3.9M
May 2019$2.8M
June 2020$7.0M
December 2023$27.7M

Management

Co-Founder

Timothy K. Lu

Board Member

Benoit Barteau

Research Scientist

Antoine Decrulle

Co-founder

Luciano Marraffini

Investor

Daniel Marhely

Board Member

Laia Crespo

Co-Founder

Timothy K. Lu

CSO & Co-founder

David Bikard

Co-founder/CEO

Xavier Duportet

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo